Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 29, 2004. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 845,000 ordinary shares of 25 pence each.
- Purchase Price: 1,181.44 pence per share.
- Transaction Date: September 28, 2004.
- Treasury Holdings: 48,028,000 shares held in Treasury following the purchase.
- Shares in Issue: 5,887,127,277 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a treasury stock purchase authorized by shareholders at the Annual General Meeting on May 17, 2004. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 845,000 share repurchase based on the disclosed price of 1,181.44 pence.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the May 17, 2004 Annual General Meeting minutes to understand the full scope of the share buyback authority granted.